Adaptive, randomized, non-inferiority trial to evaluate the efficacy of monoclonal antibodies in outpatients with mild or moderate COVID-19
收藏DataCite Commons2026-03-05 更新2025-05-10 收录
下载链接：
https://datadryad.org/dataset/doi:10.5061/dryad.tdz08kq2w
下载链接
链接失效反馈官方服务：
资源简介：
The dataset is based on the results of a trial called MANTICO (Clinical
trial number NCT05205759). The study is a non-inferiority randomised
controlled trial comparing the clinical efficacy of
bamlanivimab/etesevimab, casirivimab/imdevimab, and sotrovimab in
outpatients aged 50 or older with early COVID-19. The primary outcome was
COVID-19 progression (hospitalisation, need of supplemental oxygen
therapy, or death through day 14).
提供机构：
Dryad
创建时间：
2022-11-16
